These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 15003525)
1. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Koshimura J; Fujita H; Narita T; Shimotomai T; Hosoba M; Yoshioka N; Kakei M; Fujishima H; Ito S Biochem Biophys Res Commun; 2004 Mar; 316(1):165-9. PubMed ID: 15003525 [TBL] [Abstract][Full Text] [Related]
2. Enhanced urinary adiponectin excretion in IgA-nephropathy patients with proteinuria. Shimotomai T; Kakei M; Narita T; Koshimura J; Hosoba M; Kato M; Komatsuda A; Ito S Ren Fail; 2005; 27(3):323-8. PubMed ID: 15957550 [TBL] [Abstract][Full Text] [Related]
3. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Saraheimo M; Forsblom C; Thorn L; Wadén J; Rosengård-Bärlund M; Heikkilä O; Hietala K; Gordin D; Frystyk J; Flyvbjerg A; Groop PH; Diabetes Care; 2008 Jun; 31(6):1165-9. PubMed ID: 18346990 [TBL] [Abstract][Full Text] [Related]
4. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Kato K; Osawa H; Ochi M; Kusunoki Y; Ebisui O; Ohno K; Ohashi J; Shimizu I; Fujii Y; Tanimoto M; Makino H Clin Endocrinol (Oxf); 2008 Mar; 68(3):442-9. PubMed ID: 17970779 [TBL] [Abstract][Full Text] [Related]
5. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy. Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229 [TBL] [Abstract][Full Text] [Related]
6. Effects of aerobic exercise on microalbuminuria and enzymuria in type 2 diabetic patients. Lazarevic G; Antic S; Vlahovic P; Djordjevic V; Zvezdanovic L; Stefanovic V Ren Fail; 2007; 29(2):199-205. PubMed ID: 17365936 [TBL] [Abstract][Full Text] [Related]
7. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937 [TBL] [Abstract][Full Text] [Related]
8. [An association between adiponectin and renal dysfunction in patients with type 2 diabetes mellitus]. Galovičová A; Lazúrová I; Petrášová D Vnitr Lek; 2012 Nov; 58(11):825-9. PubMed ID: 23256827 [TBL] [Abstract][Full Text] [Related]
9. Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Matsuda M; Kawasaki F; Yamada K; Kanda Y; Saito M; Eto M; Matsuki M; Kaku K Diabet Med; 2004 Aug; 21(8):881-8. PubMed ID: 15270792 [TBL] [Abstract][Full Text] [Related]
10. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. Katavetin P; Eiam-Ong S; Suwanwalaikorn S J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002 [TBL] [Abstract][Full Text] [Related]
11. Nephelometry in the clinical assessment of glomerular proteinuria and tubular function in diabetic nephropathy. Solerte SB; Severgnini S; Locatelli M; Cerutti N; Rondanelli M; Netti MA; Ferrari E; Fioravanti M Clin Nephrol; 1997 Sep; 48(3):151-8. PubMed ID: 9342486 [TBL] [Abstract][Full Text] [Related]
12. Albuminuria: a target for treatment of type 2 diabetic nephropathy. de Zeeuw D Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686 [TBL] [Abstract][Full Text] [Related]
13. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Fujita H; Morii T; Koshimura J; Ishikawa M; Kato M; Miura T; Sasaki H; Narita T; Ito S; Kakei M Endocr J; 2006 Dec; 53(6):745-52. PubMed ID: 16966829 [TBL] [Abstract][Full Text] [Related]
14. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Ogawa Y; Goto T; Tamasawa N; Matsui J; Tando Y; Sugimoto K; Tomotsune K; Kimura M; Yasujima M; Suda T Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929 [TBL] [Abstract][Full Text] [Related]
15. Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy. Higurashi M; Ohya Y; Joh K; Muraguchi M; Nishimura M; Terawaki H; Yagui K; Hashimoto N; Saito Y; Yamada K J Diabetes Complications; 2009; 23(3):178-84. PubMed ID: 18413205 [TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a predictor of the development of diabetic nephropathy. Hinokio Y; Suzuki S; Hirai M; Suzuki C; Suzuki M; Toyota T Diabetologia; 2002 Jun; 45(6):877-82. PubMed ID: 12107732 [TBL] [Abstract][Full Text] [Related]
17. Utility of Albusure test in screening for early stage of diabetic nephropathy. Zhang J; Lnoue K; Nakashima N; Hiramatsu S; Ohashi M; Umeda F; Nawata H Chin Med J (Engl); 1994 Sep; 107(9):699-702. PubMed ID: 7805464 [TBL] [Abstract][Full Text] [Related]
18. [Possibility of early diagnosis of diabetic nephropathies]. Tornóczky J; Hoffmann E; Sziládi E; Pasztarak E; Vastag O; Kottmayer K Orv Hetil; 1989 Feb; 130(9):439-44. PubMed ID: 2648249 [TBL] [Abstract][Full Text] [Related]
19. Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Ran J; Xiong X; Liu W; Guo S; Li Q; Zhang R; Lao G Diabetes Res Clin Pract; 2010 May; 88(2):177-83. PubMed ID: 20138682 [TBL] [Abstract][Full Text] [Related]
20. Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic normotensive patients. Rubio-Guerra AF; Vargas-Robles H; Ayala GV; Escalante-Acosta BA Med Sci Monit; 2007 Aug; 13(8):CR349-52. PubMed ID: 17660723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]